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ABSTRACT
Drug reaction with eosinophilia and systemic symptoms. is a very dangerous adverse drug effect causing rashes, eosinophilia, and multiple organ 
damage. Many drugs are implicated in causing DRESS with most common ones being antimicrobials and antiepileptics. Dapsone used in the treatment 
of Hansen’s disease as a first-line agent is known for causing many side effects ranging from nausea, vomiting, insomnia, anaphylaxis, hypersensitivity 
reactions, rashes, muscle weakness, abdominal pain, and so on. Hence, we report a rare case of dapsone-induced DRESS in a tertiary care hospital in 
South India.
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INTRODUCTION
Drugs are widely used because of their ability to affect the biological 
systems of the body. The use of these drugs may also carry certain 
unwanted or unintended effects [1]. Drug reaction with eosinophilia 
and systemic symptoms (DRESS) syndrome is a severe adverse drug 
reaction usually characterized by rash, fever, lymphadenopathy, and 
single or multiple organ involvement [2]. The most commonly involved 
organ is the liver, leading to acute hepatitis-like condition. The reaction 
has a delayed onset, usually 2-6 weeks after the initiation of drug 
therapy. The estimated incidence of this syndrome varies from 1 in 
1000 to 1 in 10,000 drug exposures [3]. The overall mortality associated 
with DRESS syndrome is about 10% and occurs usually in patients 
with severe multiorgan involvement [4]. The drugs most commonly 
causing this reaction are antiepileptics (phenobarbitone, phenytoin, 
carbamazepine, and lamotrigine), antimicrobials (minocycline, 
β-lactams, sulfonamides, abacavir, and nevirapine), and allopurinol, 
sulfasalazine [5]. Here, we describe a case of dapsone-induced DRESS 
syndrome which was managed successfully using oral steroids.
CASE REPORT
Informed consent was taken from the patient. A 35-year-old male was 
referred to our hospital on 17/09/2013 with complaints of fever and 
jaundice for one week. He was diagnosed as having multibacillary 
leprosy in an outside hospital and was started on dapsone 100 mg, 
clofazimine 50 mg daily, and rifampicin 450 mg single dose monthly on 
20/08/2013. On 05/09/2013, he presented with fever, easy fatigability, 
giddiness, and jaundice. He was found to be anemic (Hb-5.6 mg/dl) 
and was given blood transfusion (2 units) there. After transfusion, 
his hemoglobin level rose to 10.1 g/dl (09/09/2013). The patient 
developed fever and deep jaundice following which he was referred 
here.
General examination of the patient at admission showed pallor, icterus, 
and lymphadenopathy with generalized papular eruptions. Ulnar nerve 
thickening and other leprotic hand changes were present. He also 
had mild hepatosplenomegaly and epigastric tenderness. The patient 
was conscious and alert and other systems’ examination were within 
normal limits. He is a reformed alcoholic and does not have any known 
drug allergies.
Laboratory investigations done on 17/09/2013 revealed the 
following. The patient had elevated total white blood cell count 
(42,800/mm3). Peripheral smear showed eosinophilia (13%) and 
atypical lymphocytosis (Table 1). The patient also had elevated 
liver enzymes - alanine aminotransferase 96 IU/L, aspartate 
aminotransferase 125 IU/L, alkaline phosphatase 1415 IU/L, gamma-
glutamyl transferase 848 IU/L, and elevated bilirubin levels - total 
bilirubin 22.2 mg/dL and direct bilirubin 17.2 mg/dL (Table 2). Renal 
function tests were within normal limits. Chest radiograph was also 
normal. Tests were negative for malaria, hepatitis B surface antigen 
and antibodies to hepatitis C virus (18/09/2013). Blood culture was 
sterile after five days of incubation (17/09/2013). The patient was also 
negative antinuclear antibodies done on 27/09/2013.
A diagnosis of DRESS syndrome was made. All antileprotic medications 
were stopped. The patient was started on oral steroids and antibiotics 
with tablet methylprednisolone 8 mg 3-0-0, injection tazillin 
(piperacillin+tazobactam) 4.5 g total dissolved solids (TDS), and 
injection metronidazole 500 mg TDS. The patient was also given tablet 
cetirizine 10 mg OD and fudic cream (fusidic acid), Dermcare shampoo 
for the skin lesions. The patient was discharged on 04/10/2013 after 
hepatic parameters started resolving and the skin lesions subsided.
DISCUSSION
The acronym DRESS syndrome was first used by Bocquet et al. [4] to 
describe a potentially life-threatening syndrome usually presenting 
with a cutaneous reaction following exposure to a drug (Dapsone in our 
case) associated with fever, hematologic abnormalities (eosinophilia 
and atypical lymphocytes), and internal organ involvement. 
4,4’-diaminodiphenylsulfone (Dapsone) is widely used for a variety of 
infectious, immune and hypersensitivity disorders, with indications 
ranging from Hansen’s disease, inflammatory disease, and insect 
bites [6].
The exact pathophysiologic mechanisms involved in its development 
are not yet fully understood. Different mechanisms have been 
proposed such as defects in drug metabolism leading to accumulation 
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Case Report
Table 1: Laboratory investigations
Date Total WBC (/mm3) Eosinophil counts (%)
17/09/2013 42800 13
01/10/2013 7100 1
WBC: White blood cell
5
Asian J Pharm Clin Res, Vol 10, Issue 5, 2017, 4-5
 Balaji et al. 
of toxic metabolites and subsequent immunological reactions, slow 
acetylation, viral reactivation (especially human herpesvirus 6, human 
herpesvirus 7, and Epstein–Barr Virus), and genetic predisposition with 
certain human leukocyte antigen alleles [7]. Dapsone after absorption 
is metabolized primarily by two pathways: N-acetylation and 
N-hydroxylation. N-hydroxylation yields a potentially toxic metabolite 
hydroxylamine which could be involved in the pathogenesis [8].
Among the different diagnostic tools available for DRESS syndrome, the 
Regi-severe cutaneous adverse reactions (SCAR) scoring system [9] and 
the Japanese study group of severe cutaneous adverse reactions to drugs 
(SCAR-J) [10] systems are the important ones. Our case meets both the 
Regi-SCAR and SCAR-J criteria for the diagnosis of DRESS syndrome as 
the patient had fever, liver involvement, and blood count abnormalities 
(leukocytosis, eosinophilia, and atypical lymphocytosis) in addition to 
the cutaneous manifestations persisting even after withdrawal of the 
offending agent. In addition, infectious and autoimmune conditions as 
the possible cause were ruled out.
Causality assessment was done using Naranjo’s scale [11], and a 
probable causal relationship was established in both the cases. Severity 
and preventability assessment was done using Hartwig’s scale [12] and 
Thornton’s scale [13], and it was found to be moderately severe and not 
preventable, respectively (Table 3)
CONCLUSION
Being a severe adverse drug reaction with considerable morbidity and 
mortality, a high level of suspicion is required to diagnose this entity early to 
improve outcome. Early diagnosis and treatment is of utmost importance 
as delay in treatment may lead to mortality. Prompt discontinuation 
of offending drug (Dapsone) and systemic steroids is the mainstay of 
treatment in DRESS along with other supportive treatment. Steroids 
should be tapered slowly; otherwise relapse of symptoms may occur.
REFERENCES
1. Antony A, Joel JJ, Shetty J, Umar NF. Identification and analysis 
of adverse drug reactions associated with cancer chemotherapy in 
hospitalized patients. Int J Pharm Pharm Sci 2016;8(7):448-51.
2. Cardoso CS, Vieira AM, Oliveira AP. DRESS syndrome: A case 
report and literature review. BMJ Case Rep 2011;2011. pii: 
Bcr0220113898.
3. Fiszenson-Albala F, Auzerie V, Mahe E, Farinotti R, 
Durand-Stocco C, Crickx B, et al. A 6-month prospective survey 
of cutaneous drug reactions in a hospital setting. Br J Dermatol 
2003;149(5):1018-22.
4. Bocquet H, Bagot M, Roujeau JC. Drug-induced pseudolymphoma 
and drug hypersensitivity syndrome (Drug Rash with eosinophilia 
and systemic symptoms: DRESS). Semin Cutan Med Surg 
1996;15(4):250-7.
5. Ben m’rad M, Leclerc-Mercier S, Blanche P, Franck N, Rozenberg F, 
Fulla Y, et al. Drug-induced hypersensitivity syndrome: Clinical 
and biologic disease patterns in 24 patients. Medicine (Baltimore) 
2009;88(3):131-40.
6. Lakshmi R, Liniya S, Vijayalakshmi S. Dapsone induced hypersensitivity 
syndrome-A case report. Int J Pharm Pharm Sci 2015;7(2):585-7.
7. Bohan KH, Mansuri TF, Wilson NM. Anticonvulsant hypersensitivity 
syndrome: Implications for pharmaceutical care. Pharmacotherapy 
2007;27(10):1425-39.
8. Kosseifi SG, Guha B, Nassour DN, Chi DS, Krishnaswamy G. The 
dapsone hypersensitivity syndrome revisited: A potentially fatal 
multisystem disorder with prominent hepatopulmonary manifestations. 
J Occup Med Toxicol 2006;1:9.
9. Kardaun SH, Sidoroff A, Valeyrie-Allanore L, Halevy S, Davidovici BB, 
Mockenhaupt M, et al. Variability in the clinical pattern of cutaneous 
side-effects of drugs with systemic symptoms: Does a DRESS 
syndrome really exist? Br J Dermatol 2007;156(3):609-11.
10. Shiohara T, Iijima M, Ikezawa Z, Hashimoto K. The diagnosis of 
a DRESS syndrome has been sufficiently established on the basis 
of typical clinical features and viral reactivations. Br J Dermatol 
2007;156(5):1083-4.
11. Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. 
A method for estimating the probability of adverse drug reactions. Clin 
Pharmacol Ther 1981;30(2):239-45.
12. Hartwig SC, Siegel J, Schneider PJ. Preventability and severity 
assessment in reporting adverse drug reactions. Am J Hosp Pharm 
1992;49(9):2229-32.
13. Schumock GT, Thornton JP. Focusing on the preventability of adverse 
drug reactions. Hosp Pharm 1992;27(6):538.
Table 2: Laboratory data
Date Total bilirubin (mg/dL) Direct bilirubin (mg/dL) AST (IU/L) ALT (IU/L) ALP (IU/L)
17/09/2013 22.2 17.2 125 96 1415
19/09/2013 21.6 16.8 114 73 1057
26/09/2013 8.7 7.3 84 175 751
28/09/2013 6.1 4.9 61 137 632
01/10/2013 4.3 3.2 43 90 402
03/10/2013 3.5 2.2 42 73 334
AST: Aspartate aminotransferase, ALT: Alanine aminotransferase, ALP: Alkaline phosphatase
Table 3: Adverse drug assessment
Scaling Case 1
Naranjo’s Probable
Hartwig’s Moderate severity
Thornton’s Not preventable
